

Davood Khalili

Date Prepared: Jan 2022

Office Address: Department of Biostatistics and Epidemiology, Research Institute for Endocrine Sciences, No. 23, Arabi st, Velenjak, Tehran, Iran

Academic Email: dkhalili@endocrine.ac.ir ; dkhalili@hsph.harvard.edu

Academic website: https://isid.research.ac.ir/Davood_Khalili

Education

Official degrees:

| | | | |
|------|-----------------------------|---------------|--|
| 2012 | Medical Specialty (MD, PhD) | Epidemiology | Shahid Beheshti University of Medical Sciences, Tehran |
| 2008 | Master (MPH) | Public Health | Shahid Beheshti University of Medical Sciences, Tehran |
| 1998 | MD | Medicine | Urmia University of Medical Sciences, Urmia, Iran |

Other advanced training

| | | |
|------|---|--|
| 2019 | Clinical Genomics | 31st Course jointly organized by ESGM, ESHG, and CEUB |
| 2016 | Iran Diabetes Advancement in Research | The American Association of Continuing Medical Education, Sanofi Group Middle East |
| 2011 | Epidemiology and Biostatistics | Erasmus Summer Program, Erasmus MC University, Rotterdam, The Netherlands |
| 2011 | Recent Developments in Epidemiologic Research | International Epidemiological Association, Edinburgh, Scotland |

Academic Appointments

Faculty member:

| | | | |
|------------|---------------------|---|---|
| 2019 - | Associate Professor | Prevention of Metabolic Disorders Research Center | Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran |
| 2013 -2018 | Assistant Professor | Prevention of Metabolic Disorders Research Center | Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran |

Other Affiliated Institutions:

| | | | |
|--------|-------------------|--|--|
| 2017 - | Lown Scholar | Department of Global Health and Population | Harvard T.H. Chan School of Public Health, Boston, MA |
| 2017 | Visiting Scholar | Department of Biomedical Data Sciences | Leiden University Medical Center (LUMC), The Netherlands |
| 2016 - | Adjunct Professor | Department of Epidemiology | School of Public Health, Iran University of Medical Sciences |

Other Professional Positions:

| | | | |
|-----------------------|------------------------------|--|---|
| 2016-2017, 2019, 2021 | Consultant | World Health Organization | By project |
| 2016-2018 | International Advisory board | The Middle East, Mediterranean and Africa Cardiovascular Clinical Trialists (CVCT, MEMA) | Annual meetings |
| 2016-2018 | Board member | The Scientific Association for Public Health in Iran (SAPHIR) | Monthly meetings |
| 2013 - | Advisory board | Clinical Trial Center, Tehran University of Medical Sciences | Annual meetings & monthly journal clubs |

Major Administrative Leadership Positions

Local

| | | |
|-----------|------------------|---|
| 2015- | Director | Department of Biostatistics and Epidemiology, Research Institute for Endocrine Sciences, Tehran |
| 2012-2015 | Research manager | Research Deputy, Research Institute for Endocrine Sciences, Tehran |

National

| | | |
|-------|-------------------|------------------------|
| 2014- | Secretary-General | Iran Cohort Consortium |
|-------|-------------------|------------------------|

Committee Service:

Local

| | | |
|--------|---|---|
| 2012 - | Member, Institutional Review Board committee | Research Institute for Endocrine Sciences |
|--------|---|---|

National

| | | |
|-----------|---|------------------------|
| 2016 - | Member, Council of education and research | Iran Cohort Consortium |
| 2019-2020 | Member, Consultant Committee for COVID-19, Tehran, Iran | |

Clinical Practice:

| | | |
|-----------|----------------------|---|
| 1999-2001 | General Practitioner | Emergency unite, Manjil Hospital, Guilan province, Iran |
| 2001-2007 | General Practitioner | Urban & rural health centers, Guilan province, Iran |

During these years I had the opportunity to acquire firsthand experience of primary and secondary care in a variety of urban and rural settings which helped me to identify the gaps and shaped and informed my future research career.

Editorial Activities

- **Ad hoc Reviewer:**

- The Lancet
- The Lancet Global Health
- Annals of Internal Medicine
- PLOS Medicine
- American Journal of Cardiology
- Journal of Clinical Epidemiology
- PLOS ONE
- BMC journals
- Preventive Medicine
- Lipids in Health and Disease
- International Journal of Information Technology & Decision Making
- Archives of Iranian Medicine
- Asia Pacific Journal of Cancer Prevention
- Journal of Research in Health Sciences
- Journal of Diabetes & Metabolic Disorders
- The Journal of Tehran Heart Center
- Iranian Journal of Epidemiology

- **Editorial Roles:**

2014 - Associate editor

International Journal of Endocrinology and Metabolism

2014 - Associate editor

Iranian Journal of Endocrinology and Metabolism

Other Review Activities

National Research Grant / Audit

| | | |
|--------|-------------------------------------|--|
| 2019 - | WHO STEPS survey committee | Ad hoc reviewer, National Institute of Health Research |
| 2018 - | Research Improvement office | Ad hoc reviewer, Research Deputy, Ministry of Health |
| 2017 - | Non-Communicable Diseases committee | Ad hoc Member, National Institute for Medical Research Development (NIMAD) |

Honors and Prizes:

| | | | |
|------|--|---|--|
| 2020 | Among top 1% Highly cited researchers | Clarivate Analytics, Essential Science Indicators (WOS-ESI) | For cited publications |
| 2019 | A letter of appreciation | Ministry of Health and Medical Education | For an elaborate review and evaluation of some research centers |
| 2017 | Honor researcher | Shahid Beheshti University of Medical Sciences, Tehran | Ranked first among assistant professors in the University |
| 2015 | Excellent Scientist | Vice-Presidency for Science and Technology, Iran | Among top 100 researchers |
| 2011 | Honor researcher | Shahid Beheshti University of Medical Sciences, Tehran | Ranked first among non-faculty members in the University |
| 2009 | Honor PhD student | Shahid Beheshti University of Medical Sciences, Tehran | Ranked first among PhD students in the school of public health |
| 2008 | Honor PhD student | Shahid Beheshti University of Medical Sciences, Tehran | Ranked first among PhD students in the school of public health |
| 2009 | A letter of appreciation | Ministry of Health and Medical Education | For contribution in the construction of Iranian Registry of Clinical Trials as a primary registry of WHO |

National & international Funded Projects

During the past 5 years

- 2019 To develop a pilot plan for IraPEN program and a no-lab prediction model for assessment of NCDs risk factors, WHO & Ministry of Health, PI
- 2018 Cost-effectiveness of the risk-based prevention of cardiovascular diseases in primary health care: National Institute for Medical Research Development (NIMAD), Ministry of Health, Iran, and Harvard T.H. Chan School of Public Health, PI
- 2018 To study the trend of risk for cardiovascular diseases during the past decade and estimate the incidence of these diseases during the next decade in Iran, National Institute for Medical Research Development (NIMAD), PI
- 2018 Validation of the American Diabetes Association (ADA) diabetes screening score in an Iranian population: Its diagnostic and prognostic power, National Institute for Medical Research Development (NIMAD), PI
- 2017 Technical support for implementation of adapted tools in demonstration site of HEART initiatives, WHO & Ministry of Health, PI
- 2016 Updating CVD risk scoring for implementation in primary health care based on updated CVD risk score, WHO recommendations and country circumstances, WHO & Ministry of Health, PI
- 2015 Comprehensive Monitoring and Evaluation of Screening Program for Congenital Hypothyroidism, Ministry of Health & Research Institute for Endocrine Sciences, Co-PI

Current

- 2021 The assessment national health system readiness/capacity for scaling up and scaling out the NCD services and Evaluate the national progress on integrating NCD services into the PHC system. WHO & Ministry of Health, Co-PI

Other funded projects and all unfunded ones, resulted in original articles, are presented as publications in peer-reviewed journals.

Teaching and Training

Teaching of Students in Academic Courses:

| | | |
|-------|--|---|
| 2016- | Clinical prediction models, for PhD students in epidemiology | Department of Epidemiology, Iran University of Medical Sciences, Tehran |
| 2017- | Advanced research methodology, for PhD by research students and physician-scientists | Shahid Beheshti University of Medical Sciences, Tehran |

Formal Teaching of Residents and Fellows:

| | | |
|-------|--|---|
| 2015- | Research Methodology for residents and fellows | Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran |
|-------|--|---|

Research Supervision of Students and Fellows:

| | | |
|--------|--|--|
| 2020 | Effect of lifestyle modification on pre-diabetes regression to normoglycemia and progression to diabetes | Supervisor, Endocrinology Fellow, Research Institute for Endocrine Sciences, Tehran |
| 2019 - | Determination of trajectory of metabolic risk factors and biomarkers in patients with prediabetes prior to the development of diabetes | Co-supervisor, Endocrinology Fellow, Research Institute for Endocrine Sciences, Tehran |
| 2019 - | The association of insulin resistance and beta-cell dysfunction with prediabetes and determination of a cut-off point for HOMA-IR and HOMA-B to predict prediabetes | Co-supervisor, Endocrinology Fellow, Research Institute for Endocrine Sciences, Tehran |
| 2019 - | Application of dynamic prediction models for three-year incident dysglycemia and type 2 diabetes using Joint modeling of longitudinal and time-to-event data in population-based cohorts | Co-supervisor, PhD student, Research Institute for Endocrine Sciences, Tehran |
| 2019 - | The risk threshold for initiating cardiovascular preventive therapy based on the evidence-based decision-making model | Co-supervisor, PhD students, Department of Epidemiology, Iran University of Medical Sciences, Tehran |
| 2018 - | A cost-effectiveness analysis of risk-based intervention for the prevention of cardiovascular disease in IraPEN: A pilot study in Iran | Co-supervisor, MS student, University of Oslo, Norway |
| 2017 - | The net benefit of using Globorisk risk score to identify high-risk individuals for cardiovascular diseases | Co-supervisor, PhD students, Department of Epidemiology, Iran University of Medical Sciences, Tehran |
| 2016 - | Effectiveness of lifestyle intervention programs for type 2 diabetes prevention in resource-constrained settings | Co-supervisor, PhD student, Non-Communicable Disease Control Unit (NCDU), University of Melbourne, Australia |

| | | |
|-----------|--|---|
| 2016-2018 | Comprehensive Monitoring and Evaluation of Screening Program for Congenital Hypothyroidism | Co-supervisor, PhD student, Research Institute for Endocrine Sciences, Tehran |
| 2016-2018 | Determining a national risk function to predict cardiovascular diseases mortality using the pooled data of population-based cohorts and surveys of Iran | Co-supervisor, PhD student, Department of Epidemiology and Biostatistics, Tehran University of Medical Sciences, Tehran |
| 2015-2017 | Assessment of lifestyle pattern among Iranian population using Self-organizing map and Latent class cluster analysis methods and its association with blood pressure | Co-supervisor, PhD student, Department of Epidemiology and Biostatistics, Tehran University of Medical Sciences, Tehran |
| 2015-2016 | The latent classes of metabolic syndrome components and the effect of the intervention program on changing these classes over time | Supervisor, MS student, Department of Epidemiology, Shahid Beheshti University University of Medical Sciences, Tehran |

Invited Presentations

Local &

National

2012-2018 At least 10 local & national invited talks regarding cohort studies, prediction models and cardiometabolic risk factors in Iran

International

2016 The situation of cardiovascular diseases in Africa and Middle East. Middle East, Mediterranean and Africa Cardiovascular Clinical Trialists (CVCT, MEMA) Forum. Abu Dhabi, United Arab Emirates

2017 WHO Package of Essential Noncommunicable (PEN) disease interventions for primary health care. Middle East, Mediterranean and Africa Cardiovascular Clinical Trialists (CVCT, MEMA) Forum. Cairo, Egypt (However, I was unable to attend because of visa)

2018 Data analysis of Cohort Studies, Department of Global Health and Population, Harvard T.H. Chan School of Public Health, US

2019 Metabolic Health in the Middle East and North Africa, Mediterranean and Africa Cardiovascular Clinical Trialists (CVCT, MEMA) Forum. Cairo, Egypt

2021 Implementing Appropriate National CVD Risk Prediction Models for clinical and Public Use, Guest Lecture, Indonesian Medical Education and Research Institute

Publications in Peer-Reviewed Journals

1. Kabootari M, Habibi Tirtashi R, Hashemina M, Bozorgmanesh M, **Khalili D**, Akbari H, Roshandel G, Hadaegh F. Clinical features, risk factors and a prediction model for in-hospital mortality among

- diabetic patients infected with COVID-19: data from a referral centre in Iran. *Public Health*. 2022 Jan;202:84-92.
2. Fahimfar N, Malekzadeh R, Fotouhi A, Mansournia MA, Sarrafzadegan N, Azizi F, Sepanlou SG, Mansourian M, Hadaegh F, Emamian MH, Poustchi H, Talaei M, Pourshams A, Roohafza H, Sharafkhah M, Samavat T, Lotfaliany M, Steyerberg EW, **Khalili D***. An office-based cardiovascular prediction model developed and validated in cohort studies of a middle-income country: Developing and validating an office-based model to predict cardiovascular mortality using cohorts of a middle-income country. *J Clin Epidemiol*. 2021 Dec 14:S0895-4356(21)00420-0. Online ahead of print.
 3. Asgari S, **Khalili D**, Mehrabi Y, Hadaegh F. Letter to the Editor Regarding "Nationwide Prevalence of Diabetes and Prediabetes and Associated Risk Factors Among Iranian Adults: Analysis of Data from PERSIAN Cohort Study". *Diabetes Ther*. 2021 Dec 3. Online ahead of print.
 4. **Khalili D***, Hadaegh F, Pirzadeh M, Azizi F. Polypill's cardiovascular and non-cardiovascular mortalities. *J Diabetes Metab Disord*. 2021 Oct 13;20(2):2133-2134.
 5. Asgari S, **Khalili D***, Zayeri F, Azizi F, Hadaegh F*. Dynamic prediction models improved the risk classification of type 2 diabetes compared with classical static models. *J Clin Epidemiol*. 2021 Dec;140:33-43.
 6. Nosratzahi S, Tasdighi E, Hadaegh F, **Khalili D**, Mahdavi M, Valizadeh M. Contribution of obesity in increasing type 2 diabetes prevalence in Iranian urban and rural adults during recent decade. *Prim Care Diabetes*. 2021 Dec;15(6):1052-1057.
 7. Rezaianzadeh A, Morasae EK, **Khalili D**, Seif M, Bahramali E, Azizi F, Bagheri P. Predicting the natural history of metabolic syndrome with a Markov-system dynamic model: a novel approach. *BMC Med Res Methodol*. 2021 Nov 27;21(1):260.
 8. Koohi F, Amiri P, Mehrabi Y, Karimi M, **Khalili D***. Development and validation of a knowledge, attitude, and practice questionnaire regarding cardiovascular diseases in an Iranian general population. *BMC Public Health*. 2021 Nov 9;21(1):2050.
 9. Khalagi K, Gharibzadeh S, **Khalili D**, Mansournia MA, Mirab Samiee S, Aghamohamadi S, Mir-Mohammad-Ali Roodaki M, Hashemi SM, Tayeri K, Namdari Tabar H, Azadmanesh K, Tabrizi JS, Mohammad K, Hajipour F, Namaki S, Raeisi A, Ostovar A. Prevalence of COVID-19 in Iran: results of the first survey of the Iranian COVID-19 Serological Surveillance programme. *Clin Microbiol Infect*. 2021 Nov;27(11):1666-1671. Epub 2021 Jun 7.
 10. **Khalili D**, Varzandeh M. Triaging diabetes research in perplexed COVID-19 resources: Avoiding research waste through a corpus-based approach. *J Res Med Sci*. 2021 Sep 30;26:83. eCollection 2021.
 11. Khodamoradi F, Nazemipour M, Mansournia N, Yazdani K, **Khalili D**, Mansournia MA. The Effects of Smoking on Metabolic Syndrome and Its Components Using Causal Methods in the Iranian Population. *Int J Prev Med*. 2021 Sep 29;12:118. eCollection 2021.
 12. Ahmadi N, Valizadeh M, Hadaegh F, Mahdavi M, Tasdighi E, Azizi F, **Khalili D**. Metabolic risk factors among prediabetic individuals and the trajectory toward the diabetes incidence. *J Diabetes*. 2021 Nov;13(11):905-914.

13. Jalali-Farahani S, Amiri P, Fakhredin H, Torshizi K, Cheraghi L, **Khalili D**, Azizi F. Health-related quality of life in men and women who experienced cardiovascular diseases: Tehran Lipid and Glucose Study. *Health Qual Life Outcomes*. 2021 Sep 26;19(1):225.
14. Dehghani M, Davoodi Z, Bidari F, Moghaddam AM, **Khalili D**, Bahrami-Motlagh H, Jamali E, Alamdari S, Hosseinpanah F, Hedayati M, Valizadeh M. Association of different pathologic subtypes of growth hormone producing pituitary adenoma and remission in acromegaly patients: a retrospective cohort study. *BMC Endocr Disord*. 2021 Sep 16;21(1):186.
15. Hosseini-Esfahani F, Alafchi B, Cheraghi Z, Doosti-Irani A, Mirmiran P, **Khalili D**, Azizi F. Using Machine Learning Techniques to Predict Factors Contributing to the Incidence of Metabolic Syndrome in Tehran: Cohort Study. *JMIR Public Health Surveill*. 2021 Sep 2;7(9):e27304.
16. Asgari S, **Khalili D***, Zayeri F, Azizi F, Hadaeagh F. Dynamic prediction models improved the risk classification of type 2 diabetes compared with classical static models. *J Clin Epidemiol*. 2021 Aug 27;140:33-43.
17. Sardarinia M, Asgari S, Hizomi Arani R, Eskandari F, Azizi F, **Khalili D**, Hadaeagh F. Incidence and risk factors of severe non-proliferative/proliferative diabetic retinopathy: More than a decade follow up in the Tehran Lipids and Glucose Study. *J Diabetes Investig*. 2021 Aug 17.
18. Cheraghi L, Amiri P, Vahedi-Notash G, Jalali-Farahani S, **Khalili D**, Azizi F. Predisposing factors of long-term responsiveness in a cardio-metabolic cohort: Tehran Lipid and Glucose Study. *BMC Med Res Methodol*. 2021 Aug 9;21(1):161
19. Farahmand M, Ramezani Tehrani F, **Khalili D**, Cheraghi L, Azizi F. Endogenous estrogen exposure and chronic kidney disease; a 15-year prospective cohort study. *BMC Endocr Disord*. 2021 Aug 4;21(1):155.
20. Toreyhi H, Asgari S, **Khalili D**, Pishgahi M, Azizi F, Hadaeagh F. Sudden cardiac death among Iranian population: a two decades follow-up of Tehran lipid and glucose study. *Sci Rep*. 2021 Aug 3;11(1):15720.
21. Nosratzahi S, Tasdighi E, Hadaeagh F, **Khalili D**, Mahdavi M, Valizadeh M. Contribution of obesity in increasing type 2 diabetes prevalence in Iranian urban and rural adults during recent decade. *Prim Care Diabetes*. 2021 Aug 2:S1751-9918(21)00123-6
22. Koochi F, Ahmadi N, Hadaeagh F, Safiee S, Azizi F, Khalili D. Trajectories of cardiovascular disease risk and their association with the incidence of cardiovascular events over 18 years of follow-up: The Tehran Lipid and Glucose study. *J Transl Med*. 2021 Jul 16;19(1):309.
23. Moazzeni SS, Hizomi Arani R, Deravi N, Hasheminia M, **Khalili D**, Azizi F, Hadaeagh F. Weight change and risk of cardiovascular disease among adults with type 2 diabetes: more than 14 years of follow-up in the Tehran Lipid and Glucose Study. *Cardiovasc Diabetol*. 2021 Jul 12;20(1):141.
24. Koochi F, **Khalili D**, Mansournia MA, Hadaeagh F, Soori H. Multi-trajectories of lipid indices with incident cardiovascular disease, heart failure, and all-cause mortality: 23 years follow-up of two US cohort studies. *J Transl Med*. 2021 Jul 3;19(1):286.
25. Ahmadi N, Valizadeh M, Hadaeagh F, Mahdavi M, Tasdighi E, Azizi F, **Khalili D**. Metabolic risk factors among prediabetic individuals and the trajectory toward the diabetes incidence. *J Diabetes*. 2021 Jun 15.
26. Khalagi K, Gharibzadeh S, **Khalili D**, Mansournia MA, Mirab Samiee S, Aghamohamadi S, Mir-Mohammad-Ali Roodaki M, Hashemi SM, Tayeri K, Namdari Tabar H, Azadmanesh K, Tabrizi JS, Mohammad K, Hajipour F, Namaki S, Raeisi A, Ostovar A. Prevalence of COVID-19 in Iran: results of

the first survey of the Iranian COVID-19 Serological Surveillance programme. *Clin Microbiol Infect.* 2021 Jun 7;S1198-743X(21)00298-6.

27. Lotfaliany M, Hadaegh F, Mansournia MA, Azizi F, Oldenburg B, **Khalili D***. Performance of Stepwise Screening Methods in Identifying Individuals at High Risk of Type 2 Diabetes in an Iranian Population. *Int J Health Policy Manag.* 2021 May 5. Online ahead of print.
28. Ahanchi NS, Hadaegh F, Azizi F, **Khalili D***. Sex- specific clustering of metabolic syndrome components and incidence of cardiovascular disease: A latent class analysis in a population-based cohort study. *J Diabetes Complications.* 2021 Jul;35(7):107942
29. Koochi F, Steyerberg EW, Cheraghi L, Abdshah A, Azizi F, **Khalili D***. Validation of the Framingham hypertension risk score in a middle eastern population: Tehran lipid and glucose study (TLGS). *BMC Public Health.* 2021 Apr 24;21(1):790.
30. Bagheri P, **Khalili D**, Seif M, Rezaianzadeh A. Dynamic behavior of metabolic syndrome progression: a comprehensive systematic review on recent discoveries. *BMC Endocr Disord.* 2021 Mar 22;21(1):54
31. Solaymani-Dodaran M, Ghanei M, Bagheri M, Qazvini A, Vahedi E, Hassan Saadat S, Amin Setarehdan S, Ansarifar A, Biganeh H, Mohazzab A, **Khalili D**, Hosein Ghazale A, Reza Heidari M, Taheri A, Khoramdad M, Mahdi Asadi M, Nazemieh M, Varshochi M, Abbasian S, Bakhtiari A, Mosaed R, Hosseini-Shokouh SJ, Shahrokhi M, Yassin Z, Ali Zohal M, Qaraati M, Rastgoo N, Sami R, Javad Eslami M, Asghari A, Namazi M, Ziaie S, Jafari-Moghaddam R, Kalantari S, Memarian M, Khodadadi J, Hossein Afshari M, Momen-Heravi M, Behzadseresht N, Reza Mobayen A, Mozafari A, Movasaghi F, Haddadzadeh Shoushtari M, Moazen J. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia. *Int Immunopharmacol.* 2021 Jun;95:107522.
32. Ahanchi NS, Tamehri Zadeh SS, **Khalili D**, Azizi F, Hadaegh F. Sex specific trajectories of central adiposity, lipid indices, and glucose level with incident hypertension: 12 years Follow-up in Tehran lipid and glucose study. *J Transl Med.* 2021 Feb 23;19(1):84.
33. Mehran L, Azizi F, Mousapour P, Cheraghi L, Yarahmadi S, Amirshakari G, Khalili D. Development of a risk prediction model for early discrimination between permanent and transient congenital hypothyroidism. *Endocrine.* 2021 Aug;73(2):374-383.
34. **Khalili D**, Bagheri P, Seif M, Rezaianzadeh A, Morasae EK, Bahramali E, Azizi F. The dynamics of metabolic syndrome development from its isolated components among Iranian adults: findings from 17 years of the Tehran lipid and glucose study (TLGS). *J Diabetes Metab Disord.* 2021 Feb 1;20(1):95-105.
35. Rahmani F, Asgari S, **Khalili D**, Habibi Moeini AS, Tohidi M, Azizi F, Hadaegh F. National trends in cardiovascular health metrics among Iranian adults using results of three cross-sectional STEPwise approaches to surveillance surveys. *Sci Rep.* 2021 Jan 8;11(1):58.
36. Hadaegh F, Asgari S, Moosaie F, Orangi M, Sarvghadi F, **Khalili D**, Azizi F. The risk and added values of the atherosclerotic cardiovascular risk enhancers on prediction of cardiovascular events: Tehran lipid and glucose study. *J Transl Med.* 2021 Jan 6;19(1):25.
37. Khalagi K, Gharibzadeh S, **Khalili D**, Mirab Samiee S, Hashemi SM, Aghamohamadi S, Mir-Mohammad-Ali Roodaki M, Tayeri K, Namdari Tabar H, Azadmanesh K, Tabrizi JS, Mohammad K, Goudarzi S, Hajipour F, Namaki S, Raeisi A, Ostovar A. Nationwide population-based surveys of Iranian COVID-19 Serological Surveillance (ICS) program: The surveys protocol. *Med J Islam Repub Iran.* 2021 May 12;35:61.

38. Amiri P, Naseri P, Vahedi-Notash G, Jalali-Farahani S, Mehrabi Y, Hamzavi-Zarghani N, Azizi F, Hadaegh F, **Khalili D***. Trends of low physical activity among Iranian adolescents across urban and rural areas during 2006-2011. *Sci Rep*. 2020 Dec 7;10(1):21318.
39. Saadati H, Baradaran HR, Danaei G, Ostovar A, Hadaegh F, Janani L, Steyerberg EW, **Khalili D***. Iranian general populations' and health care providers' preferences for benefits and harms of statin therapy for primary prevention of cardiovascular disease. *BMC Med Inform Decis Mak*. 2020 Nov 4;20(1):288.
40. Naseri P, Amiri P, Masihay-Akbar H, Jalali-Farahani S, **Khalili D**, Azizi F. Long-term incidence of cardiovascular outcomes in the middle-aged and elderly with different patterns of physical activity: Tehran lipid and glucose study. *BMC Public Health*. 2020 Nov 4;20(1):1654.
41. Erfanpoor S, Etemad K, Kazempour S, Hadaegh F, Hasani J, Azizi F, Parizadeh D, **Khalili D***. Diabetes, Hypertension, and Incidence of Chronic Kidney Disease: Is There any Multiplicative or Additive Interaction? *Int J Endocrinol Metab*. 2020 Nov 2;19(1):e101061.
42. Zahedi M, Kazemian E, Ramezani-Tehrani F, Tohidi M, Azizi F, **Khalili D**, Rahmati M, Amouzegar A. Assessment of the simultaneous effect of hypothyroidism and thyroid autoimmunity with gestational diabetes on the incidence of type 2 diabetes. *BMC Endocr Disord*. 2020 Oct 1;20(1):150.
43. Farahmand M, **Khalili D**, Ramezani Tehrani F, Amin G, Negarandeh R. Effectiveness of Echium amoenum on premenstrual syndrome: a randomized, double-blind, controlled trial. *BMC Complement Med Ther*. 2020 Sep 29;20(1):295.
44. Amiri M, Nahidi F, Yarandi RB, **Khalili D**, Tohidi M, Tehrani FR. Effects of oral contraceptives on the quality of life of women with polycystic ovary syndrome: a crossover randomized controlled trial. *Health Qual Life Outcomes*. 2020 Aug 31;18(1):293.
45. Lotfaliany M, Mansournia MA, Azizi F, Hadaegh F, Zafari N, Ghanbarian A, Mirmiran P, Oldenburg B, **Khalili D***. Long-term effectiveness of a lifestyle intervention on the prevention of type 2 diabetes in a middle-income country. *Sci Rep*. 2020 Aug 25;10(1):14173.
46. Sharifi H, Jahani Y, Mirzazadeh A, Ahmadi Gohari M, Nakhaeizadeh M, Shokoohi M, Eybpoosh S, Tohidinik HR, Mostafavi E, **Khalili D**, Hashemi Nazari SS, Karamouzian M, Haghdoost AA. Estimating COVID-19-Related Infections, Deaths, and Hospitalizations in Iran Under Different Physical Distancing and Isolation Scenarios. *Int J Health Policy Manag*. 2020 Aug 1. Online ahead of print.
47. Asgari S, Moazzeni SS, Azizi F, Abdi H, **Khalili D**, Hakemi MS, Hadaegh F. Correction To: Sex-Specific Incidence Rates and Risk Factors for Hypertension During 13 Years of Follow-up: The Tehran Lipid and Glucose Study. *Glob Heart*. 2020 Jul 29;15(1):49.
48. Hosseini-Esfahani F, Koochakpoor G, Tahmasebinejad Z, **Khalili D**, Mirmiran P, Azizi F. The association of dietary macronutrients composition with the incidence of cardiovascular disease, using iso-energetic substitution models: Tehran lipid and glucose study. *Nutr Metab Cardiovasc Dis*. 2020 Nov 27;30(12):2186-2193.
49. Malekzadeh H, Lotfaliany M, Ostovar A, Hadaegh F, Azizi F, Yoosefi M, Farzadfar F, **Khalili D**. Trends in cardiovascular risk factors in diabetic patients in comparison to general population in Iran: findings from National Surveys 2007-2016. *Sci Rep*. 2020 Jul 16;10(1):11724.
50. Fahimfar N, Fotouhi A, Mansournia MA, Malekzadeh R, Sarrafzadegan N, Azizi F, Mansourian M, Sepanlou SG, Emamian MH, Hadaegh F, Roohafza H, Hashemi H, Poustchi H, Pourshams A, Samavat T, Sharafkhan M, Talaei M, Van Klaveren D, Steyerberg EW, **Khalili D***. Prediction of Cardiovascular

Disease Mortality in a Middle Eastern Country: Performance of the Globorisk and Score Functions in Four Population-Based Cohort Studies of Iran. *Int J Health Policy Manag*. 2020 Jul 15. Online ahead of print.

51. Farahmand M, **Khalili D**, Ramezani Tehrani F, Amin G, Negarandeh R. Could Anise decrease the intensity of premenstrual syndrome symptoms in comparison to placebo? A double-blind randomized clinical trial. *J Complement Integr Med*. 2020 Jul 8. Online ahead of print.
52. Asgari S, Moosaie F, **Khalili D**, Azizi F, Hadaegh F. External validation of the European risk assessment tool for chronic cardio-metabolic disorders in a Middle Eastern population. *J Transl Med*. 2020 Jul 2;18(1):267
53. Koochi F, **Khalili D***. Knowledge, Attitude, and Practice Regarding Cardiovascular Diseases in Adults Attending Health Care Centers in Tehran, Iran. *Int J Endocrinol Metab*. 2020 Oct 1;18(3):e101612.
54. Asgari S, Lotfaliany M, Fahimfar N, Hadaegh F, Azizi F, **Khalili D**. The external validity and performance of the no-laboratory American Diabetes Association screening tool for identifying undiagnosed type 2 diabetes among the Iranian population. *Prim Care Diabetes*. 2020 Dec;14(6):672-677.
55. Farahmand M, Ramezani Tehrani F, **Khalili D**, Cheraghi L, Azizi F. Is there any association between age at menarche and anthropometric indices? A 15-year follow-up population-based cohort study. *Eur J Pediatr*. 2020 Sep;179(9):1379-1388.
56. Azimi SS, Koochi F, Aghaali M, Nikbakht R, Mahdavi M, Mokhayeri Y, Mohammadi R, Taherpour N, Nakhaeizadeh M, Khalili D, Sharifi H, Hashemi Nazari SS. Estimation of the basic reproduction number (R0) of the COVID-19 epidemic in Iran. *Med J Islam Repub Iran*. 2020 Aug 10;34:95.
57. Saatchi M, Mansournia MA, **Khalili D**, Daroudi R, Yazdani K. Estimation of Generalized Impact Fraction and Population Attributable Fraction of Hypertension Based on JNC-IV and 2017 ACC/AHA Guidelines for Cardiovascular Diseases Using Parametric G-Formula: Tehran Lipid and Glucose Study (TLGS). *Risk Manag Healthc Policy*. 2020 Aug 5;13:1015-1028.
58. Amiri M, Nahidi F, Bidhendi-Yarandi R, **Khalili D**, Tohidi M, Ramezani Tehrani F. A comparison of the effects of oral contraceptives on the clinical and biochemical manifestations of polycystic ovary syndrome: a crossover randomized controlled trial. *Hum Reprod*. 2020 Jan 9. [Epub ahead of print]
59. Lee CMY, Colagiuri S, Woodward M, Gregg EW, Adams R, Azizi F, Gabriel R, Gill TK, Gonzalez C, Hodge A, Jacobs Jr DR Jr, Joseph JJ, **Khalili D**, Magliano DJ, Mehlig K, Milne R, Mishra G, Mongraw-Chaffin M, Pasco JA, Sakurai M, Schreiner PJ, Selvin E, Shaw JE, Wittert G, Yatsuya H, Huxley RR. Comparing different definitions of prediabetes with subsequent risk of diabetes: an individual participant data meta-analysis involving 76 513 individuals and 8208 cases of incident diabetes. **BMJ Open Diabetes Res Care**. 2019 Dec 29;7(1):e000794.
60. Ramezani Tehrani F; Gulf Study Cooperative Research Group. Cost effectiveness of different screening strategies for gestational diabetes mellitus screening: study protocol of a randomized community non-inferiority trial. **Diabetol Metab Syndr**. 2019 Dec 18;11:106.
61. Akbarpour S, **Khalili D***, Zeraati H, Mansournia MA, Ramezankhani A, Ahmadi Pishkuhi M, Rostami Gooran S, Fotouhi A. Relationship between lifestyle pattern and blood pressure - Iranian national survey. **Sci Rep**. 2019 Oct 23;9(1):15194.
62. Asgari S, Khaloo P, **Khalili D**, Azizi F, Hadaegh F. Status of Hypertension in Tehran: Potential impact of the ACC/AHA 2017 and JNC7 Guidelines, 2012-2015. **Sci Rep**. 2019 Apr 23;9(1):6382.

63. Azizi F, Hadaegh F, Hosseinpanah F, Mirmiran P, Amouzegar A, Abdi H, Asghari G, Parizadeh D, Montazeri SA, Lotfaliany M, Takyar F, **Khalili D***. *Metabolic Health in the Middle East and North Africa Region*. **Lancet Diabetes Endocrinol**. 2019 Nov;7(11):866-879.
64. Danaei G, Farzadfar F, Kelishadi R, Rashidian A, Rouhani OM, Ahmadnia S, Ahmadvand A, Arabi M, Ardalan A, Arhami M, Azizi MH, Bahadori M, Baumgartner J, Beheshtian A, Djalalinia S, Doshmangir L, Haghdoost AA, Haghshenas R, Hosseinpoor AR, Islami F, Kamangar F, **Khalili D**, Madani M, Masoumi-Asl H, Mazyaki A, Mirchi A, Moradi E, Nayernouri T, Niemeier D, Omidvari AH, Peykari N, Pishgar F, Qorbani M, Rahimi K, Rahimi-Movaghar A, Tehrani FR, Rezaei N, Shahrzad S, Takian A, Tootee A, Ezzati M, Jamshidi HR, Larijani B, Majdzadeh R, Malekzadeh R. *Iran in transition*. **Lancet**. 2019 May 11;393(10184):1984-2005.
65. NCD Risk Factor Collaboration (NCD-RisC). Rising rural body-mass index is the main driver of the global obesity epidemic in adults. **Nature**. 2019 May;569(7755):260-264.
66. Khajavi A, **Khalili D**, Azizi F, Hadaegh F. *Impact of temperature and air pollution on cardiovascular disease and death in Iran: A 15-year follow-up of Tehran Lipid and Glucose Study*. **Sci Total Environ**. 2019 Apr 15;661:243-250
67. Lotfaliany M, Hadaegh F, Asgari S, Mansournia MA, Azizi F, Oldenburg B, **Khalili D***. *Non-invasive Risk Prediction Models in Identifying Undiagnosed Type 2 Diabetes or Predicting Future Incident Cases in the Iranian Population*. **Arch Iran Med**. 2019 Mar 1;22(3):116-124.
68. **Khalili D**, Asgari S, Lotfaliany M, Zafari N, Hadaegh F, Momenan AA, Nowroozpoor A, Hosseini-Esfahani F, Mirmiran P, Amiri P, Azizi F. *Long-Term Effectiveness of a Lifestyle Intervention: A Pragmatic Community Trial to Prevent Metabolic Syndrome*. **Am J Prev Med**. 2019 Mar;56(3):437-446.
69. Mehran L, **Khalili D**, Yarahmadi S, Delshad H, Mehrabi Y, Amouzegar A, Ajang N, Azizi F. *Evaluation of the congenital hypothyroidism screening programme in Iran: a 3-year retrospective cohort study*. **Arch Dis Child Fetal Neonatal Ed**. 2019 Mar;104(2):F176-F181.
70. Ahanchi NS, Hadaegh F, Alipour A, Ghanbarian A, Azizi F, **Khalili D***. *Application of Latent Class Analysis to Identify Metabolic Syndrome Components Patterns in adults: Tehran Lipid and Glucose study*. **Sci Rep**. 2019 Feb 7;9(1):1572.
71. Amiri P, Vahedi-Notash G, Naseri P, **Khalili D**, Hashemi Nazari SS, Mehrabi Y, Mahdavi Hazaveh AR, Azizi F, Hadaegh F. *National trends of pre-hypertension and hypertension among Iranian adolescents across urban and rural areas (2007-2011)*. **Biol Sex Differ**. 2019 Mar 29;10(1):15.
72. Farahmand M, Ramezani Tehrani F, **Khalili D**, Cheraghi L, Bahri Khomami M, Azizi F. *Association between duration of endogenous estrogen exposure and cardiovascular outcomes: A population - based cohort study*. **Life Sci**. 2019 Mar 15;221:335-340.
73. **Khalili D**, Azizi F, Asgari S, Zadeh-Vakili A, Momenan AA, Ghanbarian A, Eskandari F, Sheikholeslami F, Hadaegh F. *Outcomes of a Longitudinal Population-based Cohort Study and Pragmatic Community Trial: Findings from 20 Years of the Tehran Lipid and Glucose Study*. **Int J Endocrinol Metab**. 2018 Oct; 16(4 Suppl):e84748.
74. Akbarpour S, **Khalili D**, Zeraati H, Mansournia MA, Ramezankhanim A, Fotouhi A. *Lifestyle patterns in the Iranian population: Self-organizing map application*. **Caspian J Intern Med**. 2018 Summer;9(3):268-275.

75. Ramezankhani A, Harati H, Bozorgmanesh M, Tohidi M, **Khalili D**, Azizi F, Hadaegh F. *Diabetes Mellitus: Findings from 20 Years of the Tehran Lipid and Glucose Study*. **Int J Endocrinol Metab**. 2018 Oct 16;16(4 Suppl):e84784.
76. Lotfaliany M, Akbarpour S, Zafari N, Mansournia MA, Asgari S, Azizi F, Hadaegh F, **Khalili D***. *World Bank Income Group, Health Expenditure or Cardiometabolic Risk Factors? A Further Explanation of the Wide Gap in Cardiometabolic Mortality Between Worldwide Countries: An Ecological Study*. **Int J Endocrinol Metab**. 2018 Jul; 16(3):e59946.
77. Fahimfar N, **Khalili D**, Sepanlou SG, Malekzadeh R, Azizi F, Mansournia MA, Roohafza H, Emamian MH, Hadaegh F, Poustchi H, Mansourian M, Hashemi H, Sharafkhan M, Pourshams A, Farzadfar F, Steyerberg EW, Fotouhi A. *Cardiovascular mortality in a Western Asian country: results from the Iran Cohort Consortium*. **BMJ Open**. 2018 Jul 5;8(7):e020303.
78. Zafari N, Lotfaliany M, Mansournia MA, **Khalili D**, Azizi F, Hadaegh F. *Optimal cut-points of different anthropometric indices and their joint effect in prediction of type 2 diabetes: results of a cohort study*. **BMC Public Health**. 2018 Jun 5;18(1):691.
79. Bakhtiyari M, Schmidt N, Hadaegh F, **Khalili D**, Mansournia N, Asgari S, Mansournia MA. *Direct and indirect effects of central and general adiposity on cardiovascular diseases: The Tehran Lipid and Glucose Study*. **Eur J Prev Cardiol**. 2018 Jul;25(11):1170-1181.
80. Akbarpour S, **Khalili D**, Zeraati H, Mansournia MA, Ramezankhani A, Fotouhi A. *Healthy lifestyle behaviors and control of hypertension among adult hypertensive patients*. **Sci Rep**. 2018 May 31;8(1):8508.
81. Rabani S, Sardarinia M, Akbarpour S, Azizi F, **Khalili D**, Hadaegh F. *12-year trends in cardiovascular risk factors (2002-2005 through 2011-2014) in patients with cardiovascular diseases: Tehran lipid and glucose study*. **PLoS One**. 2018 May 16;13(5):e0195543.
82. Amiri P, Jalali-Farahani S, Akbar HM, Cheraghi L, **Khalili D**, Momenan A, Mirmiran P, Ghanbarian A, Hedayati M, Hosseini-Esfahani F, Azizi F. *The Effects of a Community-Based Lifestyle Intervention on Metabolic Syndrome and Its Components in Adolescents: Findings of a Decade Follow-Up*. **Metab Syndr Relat Disord**. 2018 Jun;16(5):215-223.
83. Asgari S, Abdi H, Hezaveh AM, Moghisi A, Etemad K, Beni HR, **Khalili D***. *The Burden of Statin Therapy based on ACC/AHA and NCEP ATP-III Guidelines: An Iranian Survey of Non-Communicable Diseases Risk Factors*. **Sci Rep**. 2018 Mar 21;8(1):4928
84. Mehran L, **Khalili D**, Yarahmadi S, Delshad H, Mehrabi Y, Amouzegar A, Ajang N, Azizi F. *Evaluation of the congenital hypothyroidism screening programme in Iran: a 3-year retrospective cohort study*. **Arch Dis Child Fetal Neonatal Ed**. 2018 Mar 14. pii: fetalneonatal-2017-313720.
85. Kabootari M, Asgari S, Mansournia MA, **Khalili D**, Valizadeh M, Azizi F, Hadaegh F. *Different Weight Histories and Risk of Incident Coronary Heart Disease and Stroke: Tehran Lipid and Glucose Study*. **J Am Heart Assoc**. 2018 Feb 10;7(4). pii: e006924.
86. Kazemi Jaliseh H, Ramezani Tehrani F, Behboudi-Gandevani S, Hosseinpanah F, **Khalili D**, Cheraghi L, Azizi F. *Polycystic ovary syndrome is a risk factor for diabetes and prediabetes in middle-aged but not elderly women: a long-term population-based follow-up study*. **Fertil Steril**. 2017 Dec;108(6):1078-1084.

87. Mehran L, **Khalili D**, Yarahmadi S, Amouzegar A, Mojarrad M, Ajang N, Azizi F. *Worldwide Recall Rate in Newborn Screening Programs for Congenital Hypothyroidism*. **Int J Endocrinol Metab**. 2017 Jun 25;15(3):e55451.
88. Gilani N, Kazemnejad A, Zayeri F, Hadaegh F, Azizi F, **Khalili D**. *Anthropometric Indices as Predictors of Coronary Heart Disease Risk: Joint Modeling of Longitudinal Measurements and Time to Event*. **Iran J Public Health**. 2017 Nov;46(11):1546-1554.
89. Amiri P, Jalali-Farahani S, Masihay Akbar H, Cheraghi L, **Khalili D**, Momenan A, Mirmiran P, Ghanbarian A, Hedayati M, Hosseini-Esfahani F, Azizi F. *The Effects of a Community-Based Lifestyle Intervention on Metabolic Syndrome and Its Components in Adolescents: Findings of a Decade Follow-Up*. **Metab Syndr Relat Disord**. 2018 Apr. [Epub ahead of print]
90. Saeed Kalantari, **Davood Khalili ***, Samaneh Asgari, Noushin Fahimfar, Farzad Hadaegh, Maryam Tohidi and Fereidoun Azizi. *Predictors of early adulthood hypertension during adolescence: a population-based cohort study*. **BMC Public Health** 2017 17:915
91. Mehran L, Yarahmadi S, **Khalili D**, Nazeri P, Delshad H, Abdollahi Z, Azhang N, Azizi F. *The Impact of Iodine Status on the Recall Rate of the Screening Program for Congenital Hypothyroidism: Findings from Two National Studies in Iran*. **Nutrients**. 2017 Oct 30;9(11).
92. Taravatmanesh S, **Khalili D**, Khodakarim S, Asgari S, Hadaegh F, Azizi F, Sabour S. *Determining the Factors Associated with Cardiovascular Disease Recurrence: Tehran Lipid and Glucose Study*. **J Tehran Heart Cent**. 2017 Jul;12(3):107-113.
93. Kazemijaliseh H, Ramezani Tehrani F, Behboudi-Gandevani S, **Khalili D**, Hosseinpanah F, Azizi F. *A Population-Based Study of the Prevalence of Abnormal Uterine Bleeding and its Related Factors among Iranian Reproductive-Age Women: An Updated Data*. **Arch Iran Med**. 2017 Sep;20(9):558-563.
94. Amiri M, Nahidi F, **Khalili D**, Bidhendi-Yarandi R, Ramezani Tehrani F. *Comparing the Effects of Oral Contraceptives Containing Levonorgestrel With Products Containing Antiandrogenic Progestins on Clinical, Hormonal, and Metabolic Parameters and Quality of Life in Women With Polycystic Ovary Syndrome: Crossover Randomized Controlled Trial Protocol*. **JMIR Res Protoc**. 2017 Sep 29;6(9):e191.
95. Mansournia MA, Holakouie-Naieni K, Fahimfar N, Almasi-Hashiani A, Cheraghi Z, Ayubi E, Hadaegh F, Eskandari F, Azizi F, **Khalili D***. *Risk of Coronary Heart Events Based on Rose Angina Questionnaire and ECG Besides Diabetes and Other Metabolic Risk Factors: Results of a 10-Year Follow-up in Tehran Lipid and Glucose Study*. **Int J Endocrinol Metab**. 2017 Apr 24;15(2):e42713.
96. Farahmand M, Ramezani Tehrani F, **Khalili D**, Amin G, Negarandeh R. *Factors associated with the severity of premenstrual syndrome among Iranian college students*. **J Obstet Gynaecol Res**. 2017 Nov;43(11):1726-1731.
97. Ramezankhani A, Bagherzadeh-Khiabani F, **Khalili D**, Azizi F, Hadaegh F. *A new look at risk patterns related to coronary heart disease incidence using survival tree analysis: 12 Years Longitudinal Study*. **Sci Rep**. 2017 Jun 12;7(1):3237.
98. Daneshpour MS, Fallah MS, Sedaghati-Khayat B, Guity K, **Khalili D**, Hedayati M, Ebrahimi A, Hajsheikholeslami F, Mirmiran P, Ramezani Tehrani F, Momenan AA, Ghanbarian A, Amouzegar A, Amiri P, Azizi F. *Rationale and Design of a Genetic Study on Cardiometabolic Risk Factors: Protocol for the Tehran Cardiometabolic Genetic Study (TCGS)*. **JMIR Res Protoc**. 2017 Feb 23;6(2):e28.

99. Peter Ueda, Mark Woodward, Yuan Lu, Kaveh Hajifathalian, Rihab Al-Wotayan, Carlos A Aguilar-Salinas, Alireza Ahmadvand, Fereidoun Azizi, James Bentham, Renata Cifkova, Mariachiara Di Cesare, Louise Eriksen, Farshad Farzadfar, Trevor S Ferguson, Nayu Ikeda, **Davood Khalili**, Young-Ho Khang, Vera Lanska, Luz León-Muñoz, Dianna Magliano, Paula Margozzini, Kelias P Msyamboza, Gerald N Mutungi, Kyungwon Oh, Sophal Oum, Fernando Rodríguez-Artalejo, Rosalba Rojas-Martinez, Gonzalo Valdivia, Rainford Wilks, Jonathan E Shaw, Gretchen A Stevens, Janne Tolstrup, Bin Zhou, Joshua A Salomon, Majid Ezzati, Goodarz Danaei. *Laboratory-based and office-based cardiovascular risk scores and charts for prediction of 10-year risk of fatal and non-fatal cardiovascular disease in 182 countries: a pooled analysis.* **Lancet Diabetes Endocrinol.** 2017 Mar;5(3):196-213.
100. Golozar A, **Khalili D**, Etemadi A, Poustchi, Fazeltabar, Hosseini, Kamangar F, Khoshnia M, Islami F, Hadaegh F, Brennan P, Boffetta P, Abnet CC, Dawsey SM, Azizi F, Malekzadeh R, Danaei G. *White rice intake and incidence of type-2 diabetes: analysis of two prospective cohort studies from Iran.* **BMC Public Health.** 2017, 31;17(1):133.
101. Barzin M, Motamedi MA, Serahati S, Khalaj A, Arian P, Valizadeh M, **Khalili D**, Azizi F, Hosseinpanah F. *Comparison of the Effect of Gastric Bypass and Sleeve Gastrectomy on Metabolic Syndrome and its Components in a Cohort: Tehran Obesity Treatment Study (TOTS).* **Obes Surg.** 2017 Jul;27(7):1697-1704
102. Eslami A, Mozaffary A, Derakhshan A, Azizi F, **Khalili D**, Hadaegh F. *Sex-specific incidence rates and risk factors of premature cardiovascular disease. A long term follow up of the Tehran Lipid and Glucose Study.* **Int J Cardiol.** 2017. 15;227:826-832.
103. Asgari S, Barzin M, Hosseinpanah F, Hadaegh F, Azizi F, **Khalili D***. *Obesity Paradox and Recurrent Coronary Heart Disease in a Population-Based Study: Tehran Lipid and Glucose Study.* **Int J Endocrinol Metab.** 2016 Apr 16;14(2).
104. Panahi MH, Hadaegh F, Yavari P, Kazempour-Ardebili S, Mehrabi Y, Azizi F, **Khalili D***. *A Challenging Interaction of Chronic Kidney Disease With Other Metabolic Disorders: Paradoxes in Cardiometabolic Risk Factors.* **Iran J Kidney Dis.** 2016 Sep;10(5):274-281.
105. Cheraghi Z, Mirmiran P, Mansournia MA, Moslehi N, **Khalili D**, Nedjat S. *The association between nutritional exposures and metabolic syndrome in the Tehran Lipid and Glucose Study (TLGS): a cohort study.* **Public Health.** 2016;140:163-171.
106. NCD Risk Factor Collaboration (NCD-RisC). *A century of trends in adult human height.* **Elife.** 2016 Jul 26;5.
107. Shaseb E, Tohidi M, Abbasinazari M, **Khalili D**, Talasaz AH, Omrani H, Hadaegh F. *The effect of a single dose of vitamin D on glycemic status and C-reactive protein levels in type 2 diabetic patients with ischemic heart disease: a randomized clinical trial.* **Acta Diabetol.** 2016 Aug;53(4):575-82.
108. Ghasemzadeh Z, Abdi H, Asgari S, Tohidi M, **Khalili D**, Valizadeh M, Moeini S, Eidkhani V, Azizi F, Hadaegh F. *Divergent pathway of lipid profile components for cardiovascular disease and mortality events: Results of over a decade follow-up among Iranian population.* **Nutr Metab (Lond).** 2016 Jun 24;13:43.
109. Helgadottir A, Gretarsdottir S, Thorleifsson G, Hjartarson E, Sigurdsson A, Magnusdottir A, Jonasdottir A, Kristjansson H, Sulem P, Oddsson A, Sveinbjornsson G, Steinthorsdottir V, Rafnar T, Masson G, Jonsdottir I, Olafsson I, Eyjolfsson GI, Sigurdardottir O, Daneshpour MS, **Khalili D**, Azizi F, Swinkels DW, Kiemeny L, Quyyumi AA, Levey AI, Patel RS, Hayek SS, Gudmundsdottir IJ, Thorgeirsson G, Thorsteinsdottir U, Gudbjartsson DF, Holm H, Stefansson K. *Variants with large effects on blood lipids*

and the role of cholesterol and triglycerides in coronary disease. **Nature Genetics**. 2016 Jun;48(6):634-9.

110. Ramezani Tehrani F, Montazeri SA, **Khalili D**, Cheraghi L, Broekmans FJ, Momenan AA, de Kat AC, Azizi F. *Age-specific anti-Müllerian hormone and electrocardiographic silent coronary artery disease*. **Climacteric**. 2016 Aug;19(4):344-8
111. Bagherzadeh-Khiabani F, Steyerberg EW, **Khalili D***. *THE AUTHORS REPLY to Letter to the Editor re: Bagherzadeh-Khiabani et al.* **J Clin Epidemiol**. 2016 Jul;75:131-2.
112. NCD Risk Factor Collaboration (NCD-RisC). *Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants*. **Lancet**. 2016 Apr 9;387(10027):1513-30.
113. NCD Risk Factor Collaboration (NCD-RisC). *Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants*. **Lancet**. 2016 Apr 2;387(10026):1377-96.
114. Khiabani FB, Ramezankhani A, Azizi F, Hadaegh F, Steyerberg EW, **Khalili D***. *A tutorial on variable selection for clinical prediction models: Feature selection methods in data-mining could improve the results*. **J Clin Epidemiol**. 2016 Mar;71:76-85.
115. Hadaegh F, Derakhshan A, Mozaffary A, Hasheminia M, **Khalili D**, Azizi F. *Twelve-Year Cardiovascular and Mortality Risk in Relation to Smoking Habits in Type 2 Diabetic and Non-Diabetic Men: Tehran Lipid and Glucose Study*. **PLoS One**. 2016 Mar 1;11(3):e0149780.
116. Barzin M, Hosseiniapanah, Motamedi MA, Shapoori P, Arian P, Daneshpour MA, Asghari G, Teymoornejad A, Eslamifar A, **Khalili D**, Jodeiri B, Alamdari S, Azizi F, Khalaj A. *Bariatric Surgery for Morbid Obesity: Tehran Obesity Treatment Study (TOTS) Rationale and Study Design*. **JMIR Res Protoc**. 2016 Jan 20;5(1):e8.
117. Afsharian S, Akbarpour S, Abdi H, Sheikholeslami F, Moeini AS, **Khalili D**, Momenan AA, Azizi F, Hadaegh F. *Risk factors for cardiovascular disease and mortality events in adults with type 2 diabetes: a 10 year follow-up: Tehran lipid and glucose study*. **Diabetes Metab Res Rev**. 2016 Sep;32(6):596-606.
118. Asgari S, **Khalili D**, Mehrabi Y, Kazempour-Ardebili S, Azizi F, Hadaegh F. *Incidence and risk factors of isolated systolic and diastolic hypertension: a 10 year follow-up of the Tehran Lipids and Glucose Study*. **Blood Press**. 2016 Jun;25(3):177-83.
119. Hadaegh F, Derakhshan A, Zafari N, **Khalili D**, Mirbolouk M, Saadat N, Azizi F. *Pre-diabetes tsunami: incidence rates and risk factors of pre-diabetes and its different phenotypes over 9 years of follow-up*. **Diabet Med**. 2015 Nov 25. doi: 10.1111/dme.13034. [Epub ahead of print]
120. Masudi S, Yavari P, Mehrabi Y, Azizi F, **Khalili D***. *Underestimating the Effect of Lipids on Cardiovascular Events: Regression Dilution Bias in the Population-Based Cohort of Tehran Lipid and Glucose Study*. **Int J Endocrinol Metab**. 2015 Oct 3;13(4):e27528.
121. Hadaegh F, Hasheminia M, Abdi H, **Khalili D**, Bozorgmanesh M, Arshi B, Azizi F. *Prehypertension Tsunami: A Decade Follow-Up of an Iranian Adult Population*. **PLoS One**. 2015 Oct 6;10(10).
122. Hashemi Nazari SS, Shakiba M, **Khalili D***, Hadaegh F, Tohidi M, Azizi F. *High-density lipoprotein cholesterol, a protective or a risk factor for developing coronary heart disease? Tehran Lipid and Glucose Study*. **J Clin Lipidol**. 2015 Jul-Aug;9(4):553-8.

123. Masudi S, Yavari P, Mehrabi Y, **Khalili D**, Azizi F. *Regression dilution bias in blood pressure and body mass index in a longitudinal population-based cohort study.* **J Res Health Sci.** 2015 Spring;15(2):77-82.
124. Kazemijalish H, Ramezani Tehrani F, Behboudi-Gandevani S, Hosseinpanah F, **Khalili D**, Azizi F. *The Prevalence and Causes of Primary Infertility in Iran: A Population-Based Study.* **Glob J Health Sci.** 2015 Apr 19;7(6):45001.
125. Hajifathalian K, Ueda P, Lu Y, Woodward M, Ahmadvand A, Aguilar-Salinas CA, Azizi F, Cifkova R, Di Cesare M, Eriksen L, Farzadfar F, Ikeda N, **Khalili D**, Khang YH, Lanska V, León-Muñoz L, Magliano D, Msyamboza KP, Oh K, Rodríguez-Artalejo F, Rojas-Martinez R, Shaw JE, Stevens GA, Tolstrup J, Zhou B, Salomon JA, Ezzati M, Danaei G. *A novel risk score to predict cardiovascular disease risk in national populations (Glorobrisk): a pooled analysis of prospective cohorts and health examination surveys.* **Lancet Diabetes Endocrinol.** 2015 May;3(5):339-55.
126. Azimi SS, **Khalili D***, Hadaegh F, Yavari P, Mehrabi Y, Azizi F. *Calculating population attributable fraction for cardiovascular risk factors using different methods in a population based cohort study.* **J Res Health Sci.** 2015 Winter;15(1):22-7.
127. Khalili M, Vasei M, **Khalili D**, Alimoghaddam K, Sadeghizadeh M, Mowla SJ. *Downregulation of the Genes Involved in Reprogramming (SOX2, c-MYC, miR-302, miR-145, and P21) in Gastric Adenocarcinoma.* **J Gastrointest Cancer.** 2015 Sep;46(3):251-8.
128. **Khalili D**, Asgari S, Hadaegh F, Steyerberg EW, Rahimi K, Fahimfar N, Azizi F. *A new approach to test validity and clinical usefulness of the 2013 ACC/AHA guideline on statin therapy: A population-based study.* **Int J Cardiol.** 2015 Apr 1;184:587-94.
129. Kazemi H, Ramezani Tehrani F, Minooe S, **Khalili D**, Azizi F. *Women self-perception of excess hair growth, as a predictor of clinical hirsutism: a population-based study.* **J Endocrinol Invest.** 2015 Aug;38(8):923-8.
130. Derakhshan A, Tohidi M, Arshi B, **Khalili D**, Azizi F, Hadaegh F. *Relationship of hyperinsulinaemia, insulin resistance and β -cell dysfunction with incident diabetes and pre-diabetes: the Tehran Lipid and Glucose Study.* **Diabet Med.** 2015 Jan;32(1):24-32.
131. Ayubi E, **Khalili D***, Delpisheh A, Hadaegh F, Azizi F. *Factor analysis of metabolic syndrome components and predicting type 2 diabetes: Results of 10-year follow-up in a Middle Eastern population.* **J Diabetes.** 2015 Nov;7(6):830-8.
132. Jahangiri-Noudeh Y, Akbarpour S, Lotfaliany M, Zafari N, **Khalili D**, Tohidi M, Mansournia MA, Azizi F, Hadaegh F. *Trends in cardiovascular disease risk factors in people with and without diabetes mellitus: a Middle Eastern cohort study.* **PLoS One.** 2014 Dec 2;9(12):e112639.
133. Ramezankhani A, Pournik O, Shahrabi J, Azizi F, Hadaegh F, **Khalili D***. *The Impact of Oversampling with SMOTE on the Performance of 3 Classifiers in Prediction of Type 2 Diabetes.* **Med Decis Making.** 2016 Jan;36(1):137-44.
134. Ramezankhani A, Pournik O, Shahrabi J, **Khalili D**, Azizi F, Hadaegh F. *Applying decision tree for identification of a low risk population for type 2 diabetes. Tehran Lipid and Glucose Study.* **Diabetes Res Clin Pract.** 2014 Sep;105(3):391-8.
135. Farahmand M, Ramezani Tehrani F, Simbar M, Mehrabi Y, **Khalili D**, Azizi F. *Does metabolic syndrome or its components differ in naturally and surgically menopausal women?* **Climacteric.** 2014 Aug;17(4):348-55.

136. Kabir A, **Khalili D**. *Built-in bias in HCV clearance in acute HCV infection*. **J Hepatol**. 2014 Feb;60(2):461.
137. **Khalili D**, Sheikholeslami FH, Bakhtiyari M, Azizi F, Momenan AA, Hadaegh F. *The incidence of coronary heart disease and the population attributable fraction of its risk factors in Tehran: a 10-year population-based cohort study*. **PLoS One**. 2014 Aug 27;9(8):e105804.
138. Derakhshan A, Sardarinia M, **Khalili D**, Momenan AA, Azizi F, Hadaegh F. *Sex specific incidence rates of type 2 diabetes and its risk factors over 9 years of follow-up: Tehran Lipid and Glucose Study*. **PLoS One**. 2014 Jul 16;9(7):e102563.
139. Panahi MH, Yavari P, **Khalili D**, Mehrabi Y, Hadaegh F, Azizi F. *Obesity paradox: coronary heart disease incidence in patients with chronic kidney disease and metabolic syndrome*. **Iranian Journal of Epidemiology**. 2015 Jun 15;11(1):72-81. (Persian Article)
140. Panahi MH, Yavari P, **Khalili D**, Mehrabi Y, Hadaegh F, Azizi F. *The Risk of Chronic Kidney Disease and Metabolic Syndrome in the Incidence of Coronary Heart Disease: Tehran Lipid and Glucose Study*. **Iranian Journal of Epidemiology**. 2014 Mar 15;9(4):10-20. (Persian Article)
141. Tohidi M, Bozorgmanesh M, Mohebi R, **Khalili D**, Saadat N, Khorrami N, Azizi F, Hadaegh F. *Non-linear association between 25-hydroxyvitamin D and the incidence of type 2 diabetes: a community-based nested case-control study*. **Diabet Med**. 2013 Aug;30(8):934-8.
142. Samadi S, Bozorgmanesh M, **Khalili D**, Momenan A, Sheikholeslami F, Azizi F, Hadaegh F. *Hypertriglyceridemic waist: the point of divergence for prediction of CVD vs. mortality: Tehran Lipid and Glucose Study*. **Int J Cardiol**. 2013 May 10;165(2):260-5.
143. **Khalili D**, Hadaegh F, Steyerberg EW. *The authors reply*. **Am J Epidemiol**. 2013 Apr 15;177(8):865-6.
144. Jahangiri Noudeh Y, Hadaegh F, Vatankhah N, Momenan AA, Saadat N, **Khalili D**, Azizi F. *Wrist circumference as a novel predictor of diabetes and prediabetes: results of cross-sectional and 8.8-year follow-up studies*. **J Clin Endocrinol Metab**. 2013 Feb;98(2):777-84.
145. Hadaegh F, Mohebi R, **Khalili D**, Hasheminia M, Sheikholeslami F, Azizi F. *High normal blood pressure is an independent risk factor for cardiovascular disease among middle-aged but not in elderly populations: 9-year results of a population-based study*. **J Hum Hypertens**. 2013 Jan;27(1):18-23.
146. Mobasheri F, **Khalili D**, Mehrabi Y, Hadaegh F, Movahedi M, Momenan AA, Ghanbarian A, Zayeri F, Azizi F. *Effects of Lifestyle Modification Education on Prevalence of General and Central Obesity in Adults: Tehran Lipid and Glucose Study*" **Journal of Isfahan Medical School**. 2012;30:205. (Persian article)
147. Azimi, S. S., **Khalili D**, Hadaegh F, Mehrabi Y, Yavari P, and Azizi F. *Direct Estimate of Population Attributable Fraction of Risk Factors for Cardiovascular Diseases: Tehran Glucose and Lipid Study*. **Iranian Journal of Epidemiology**. 2012;4:9-18. (Persian article)
148. Mohammadreza B, Farzad H, **Davoud K**, Fereidoun A. *Prognostic significance of the complex "Visceral Adiposity Index" vs. simple anthropometric measures: Tehran lipid and glucose study*. **Cardiovasc Diabetol**. 2012 Mar 7;11:20.
149. **Khalili D**, Hadaegh F, Fahimfar N, Shafiee G, Sheikholeslami F, Ghanbarian A, Azizi F. *Does an electrocardiogram add predictive value to the rose angina questionnaire for future coronary heart*

disease? 10-year follow-up in a Middle East population. **J Epidemiol Community Health**. 2012 Dec;66(12):1104-9.

150. Hadaegh F, Jahangiri Noudeh Y, Tohidi M, Vatankhah N, **Khalili D**, Mohebi R, Azizi F. *Change in general and central adiposity measures in prediction of incident dysglycemia; Tehran Lipid and Glucose Study*. **Prev Med**. 2012 Dec;55(6):608-12.
151. Fahimfar N, **Khalili D**, Mohebi R, Azizi F, Hadaegh F. *Risk factors for ischemic stroke; results from 9 years of follow-up in a population based cohort of Iran*. **BMC Neurol**. 2012 Oct 2;12:117.
152. Hatami M, Tohidi M, Mohebi R, **Khalili D**, Azizi F, Hadaegh F. *Adolescent lipoprotein classifications according to National Health and Nutrition Examination Survey (NHANES) vs. National Cholesterol Education Program (NCEP) for predicting abnormal lipid levels in adulthood in a Middle East population*. **Lipids Health Dis**. 2012 Aug 31;11:107.
153. **Khalili D**, Hadaegh F, Soori H, Steyerberg EW, Bozorgmanesh M, Azizi F. *Clinical usefulness of the Framingham cardiovascular risk profile beyond its statistical performance: the Tehran Lipid and Glucose Study*. **Am J Epidemiol**. 2012 Aug 1;176(3):177-86.
154. Hadaegh F, Zabetian A, **Khalili D**, Safarkhani M, Philip T James W, Azizi F. *A new approach to compare the predictive power of metabolic syndrome defined by a joint interim statement versus its components for incident cardiovascular disease in Middle East Caucasian residents in Tehran*. **J Epidemiol Community Health**. 2012 May;66(5):427-32.
155. Hatami M, Hadaegh F, **Khalili D**, Sheikholeslami F, Azizi F. *Family history of diabetes modifies the effect of blood pressure for incident diabetes in Middle Eastern women: Tehran Lipid and Glucose Study*. **J Hum Hypertens**. 2012 Feb;26(2):84-90.
156. Karami M, **Khalili D**, Eshrati B. *Estimating the proportion of diabetes to the attributable burden of cardiovascular diseases in Iran*. **Iran J Public Health**. 2012;41(8):50-5.
157. Tohidi M, Hasheminia M, Mohebi R, **Khalili D**, Hosseinpanah F, Yazdani B, Nasiri AA, Azizi F, Hadaegh F. *Incidence of chronic kidney disease and its risk factors, results of over 10 year follow up in an Iranian cohort*. **PLoS One**. 2012;7(9):e45304.
158. **Khalili D**, Mosavi-Jarrahi A, Eskandari F, Mousavi-Jarrahi Y, Hadaegh F, Mohagheghi M, Azizi F. *Evaluation of cause of deaths' validity using outcome measures from a prospective, population based cohort study in Tehran, Iran*. **PLoS One**. 2012;7(2):e31427.
159. Hadaegh F, Bozorgmanesh M, Safarkhani M, **Khalili D**, Azizi F. *Predictability of body mass index for diabetes: affected by the presence of metabolic syndrome?*. **BMC Public Health**. 2011 May 25;11:383.
160. Solaymani-Dodaran M, **Khalili D**, Hosseini H, Najafi L, Kamali K, Ranjbar P, Tavakoli H, Ostovar A. *Iranian Registry of Clinical Trials two years on and the timing of registrations*. **J Evid Based Med**. 2011;4(3):168-71.
161. Hadaegh F, Fahimfar N, **Khalili D**, Sheikholeslami F, Azizi F. *New and known type 2 diabetes as coronary heart disease equivalent: results from 7.6 year follow up in a Middle East population*. **Cardiovasc Diabetol**. 2010 Dec 4;9:84.
162. Azizi F, Hadaegh F, **Khalili D**, Esteghamati A, Hosseinpanah F, Delavari A, Larijani B, Mirmiran P, Zabetian A, Mehrabi Y, Kelishadi R, Aghajani H. *Appropriate definition of metabolic syndrome among Iranian adults: report of the Iranian National Committee of Obesity*. **Arch Iran Med**. 2010 Sep;13(5):426-8.

163. Azizi F, **Khalili D**, Aghajani H, Esteghamati A, Hosseinpanah F, Delavari A, Larijani B, Mirmiran P, Mehrabi Y, Kelishadi R, Hadaegh F. *Appropriate waist circumference cut-off points among Iranian adults: the first report of the Iranian National Committee of Obesity*. **Arch Iran Med**. 2010 May;13(3):243-4.
164. Hadaegh F, Zabetian A, Sarbakhsh P, **Khalili D**, James WP, Azizi F. *Appropriate cutoff values of anthropometric variables to predict cardiovascular outcomes: 7.6 years follow-up in an Iranian population*. **Int J Obes (Lond)**. 2009 Dec;33(12):1437-45.
165. Hadaegh F, **Khalili D**, Fahimfar N, Tohidi M, Eskandari F, Azizi F. *Glucose intolerance and risk of cardiovascular disease in Iranian men and women: results of the 7.6-year follow-up of the Tehran Lipid and Glucose Study (TLGS)*. **J Endocrinol Invest**. 2009 Oct;32(9):724-30.
166. Solaymani-Dodaran M, Ostovar A, **Khalili D**, Vasei M. *Iranian Registry of Clinical Trials: path and challenges from conception to a World Health Organization primary register*. **J Evid Based Med**. 2009 Feb;2(1):32-5.
167. Hadaegh F, **Khalili D**, Ghasemi A, Tohidi M, Sheikholeslami F, Azizi F. *Triglyceride/HDL-cholesterol ratio is an independent predictor for coronary heart disease in a population of Iranian men*. **Nutr Metab Cardiovasc Dis**. 2009 Jul;19(6):401-8.

Book Chapters (in Persian)

1. **Khalili D**, Azizi F, Sadeghi-Hasanabadi A. An Introduction to Non-Communicable Diseases. In Azizi F, Janghorbani M, Hatami H. *Epidemiology and Control of Common Diseases in Iran*, Forth edition. Tehran: Khosravi press, 2017
2. Delshad H, **Khalili D**, Azizi F. Diabetes. In Azizi F, Janghorbani M, Hatami H. *Epidemiology and Control of Common Diseases in Iran*, Forth edition. Tehran: Khosravi press, 2017
3. **Khalili D**, Hadaegh F. Hypertension. In Yavari P. *Epidemiology Textbook of Prevalent Diseases in Iran*. Volume 2 – Noncommunicable Diseases. Tehran: Gapnashr, 2014
4. Delshad H, **Khalili D**. Diabetes. In Yavari P. *Epidemiology textbook of Prevalent Diseases in Iran*. Volume 2 – Noncommunicable Diseases. Tehran: Gapnashr, 2014
5. Hosseinpanah F, Barzin M, **Khalili D**. Obesity. In Yavari P. *Epidemiology textbook of Prevalent Diseases in Iran*. Volume 2 – Noncommunicable Diseases. Tehran: Gapnashr, 2014

International Conference Presentations

2019

Long-term effectiveness of a community-wide lifestyle intervention on the prevention of type 2 diabetes in Iran. *IDF Congress 2019, Busan, Korea*

-
- 2019
Performance of stepwise screening methods in identifying those at high risk of type 2 diabetes in an Iranian population. *IDF Congress 2019, Busan, Korea*
-
- 2019
The validity and performance of the ADA screening tool for identifying undiagnosed type 2 diabetes in Iran. *IDF Congress 2019, Busan, Korea*
-
- 2018
Cost-Sensitive Measures Vs. Youden`s Index to Determine an Optimal Threshold for Biomarkers: A Practical Approach to Define Pre-Diabetes. *SMDM 17th Biennial European Conference, Leiden, The Netherlands. (Oral)*
- 2018
Score Risk Function to Predict Cardiovascular Disease Mortality in a Population Outside of Europe: Performance and Challenges. *SMDM 17th Biennial European Conference, Leiden, The Netherlands. (Oral)*
- 2018
Consistency between Score and Globorisk Prediction Models for Cardiovascular Disease Mortality in a Western Asian Country. *SMDM 17th Biennial European Conference, Leiden, The Netherlands.*
- 2018
Validation, Calibration, and Clinical Usefulness of FINDRISC, AUSDRISK, ADA Risk Scores for Predicting 5-year Incidence of Diagnosed Type 2 Diabetes in a Middle Eastern Population; the Tehran Lipid and Glucose study. *SMDM 17th Biennial European Conference, Leiden, The Netherlands.*
- 2016
A Novel Approach to Determine Potential Predictors of Diabetes Among Pre-Diabetic Women: A Population-Based Cohort Study. *17th International Congress of Endocrinology, Beijing, China.*
- 2016
Incorporating Clinical Consequences to Screen for Pre-Diabetes: A Cost-Sensitive Cut-Off for Fasting Plasma Glucose. *17th International Congress of Endocrinology, Beijing, China.*
- 2016
Cardiometabolic Mortality Rate Across Countries Is More Dependent on The Prevalence of Diabetes in Men Than on This Prevalence in Women: An Ecological Study. *17th International Congress of Endocrinology, Beijing, China.*
- 2016
A New Approach to Metabolic Syndrome Components Using Latent Class Analysis (LCA): Dysglycemia Apart From Other Components. *17th International Congress of Endocrinology, Beijing, China.*
- 2016
The Number Needed to Treat for Intensive Statin Therapy in Diabetic Men and Women According to 2013 ACC/AHA Guideline. *17th International Congress of Endocrinology, Beijing, China.*

- 2015
A Systematic Approach to Variable Selection Methods Used In Data-Mining: A Practice in Epidemiology. *European Congress in Epidemiology, Maastricht, The Netherlands. (Oral)*
- 2015
Negative Interaction Between Chronic Kidney Disease and Metabolic Syndrome for Coronary Heart Disease Incidence in Non-Obese Individuals: Risk Factors Paradox. *European Congress in Epidemiology, Maastricht, The Netherlands.*
- 2015
Risk of Coronary Heart Events in Symptomatic and Asymptomatic Individuals: 10 Years Follow-Up in Tehran Lipid and Glucose Study (TLGS). *European Congress in Epidemiology, Maastricht, The Netherland.*
- 2015
Incidence of Recurrent CHD and the Impact of Obesity Paradox in a Population-Based Study: Tehran Lipid and Glucose Study. *European Congress in Epidemiology, Maastricht, The Netherlands.*
- 2015
Application of Net Benefit Fraction to Select Cut-Off for Medical Markers. *European Congress in Epidemiology, Maastricht, The Netherlands.*
- 2014
The Application of Risk Estimation in Guidelines for Statin Therapy. *10th International Congress of Endocrine Disorders, Tehran, Iran. (Oral)*
- 2011
Net Benefit Fraction as a modified Population Attributable Fraction to evaluate the clinical performance of a risk function. *19th World Congress of Epidemiology, Edinburgh, Scotland.*
- 2011
Clinical usefulness of Framingham Cardiovascular Risk Profile during a 10-year follow up in Iran. *19th World Congress of Epidemiology, Edinburgh, Scotland.*
- 2011
An approach to compare the importance of different cardiovascular exposures as continuous variables. *19th World Congress of Epidemiology, Edinburgh, Scotland.*
- 2011
Rose angina vs silent ischemia in prediction of coronary heart disease: Tehran Lipid and Glucose Study. *19th World Congress of Epidemiology, Edinburgh, Scotland.*
- 2011
Different methods to calculate population attributable fraction of risk factors for cardiovascular diseases: Tehran Lipid and Glucose Study (TLGS). *19th World Congress of Epidemiology, Edinburgh, Scotland.*
- 2011
Estimating the attributable burden of cardiovascular disease following reducing the prevalence of diabetes to theoretical and feasible minimum risk level. *19th World Congress of Epidemiology, Edinburgh, Scotland.*

2009

Glucose intolerance and risk of cardiovascular disease in Iranian men and women. *the 8th International Congress on Endocrine Disorders, Tehran, Iran. (Oral)*

2009

Triglyceride/HDL-cholesterol ratio is an independent predictor for coronary heart disease in Iranian men population. *3rd International Congress on Prediabetes and the Metabolic Syndrome, Nice, France.*

Research Interests

- Prevention and control of Non-Communicable Diseases mainly Cardiovascular Diseases and Diabetes
- Research methodology for clinical and public health research
- Clinical prediction models